INNOCAN PHARMA CORPO

INNO
Delayed Quote. Delayed  - 04/21 03:59:59 pm
0.5CAD +2.04%

Innocan Pharma Announces Proceeds of CDN $ 3.1M from the Exercise of Warrants Since January 1, 2021

03/16/2021 | 03:20pm

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 16, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since January 1, 2021, it has received proceeds of approximately CDN $3.1M as a result of the exercise of approximately 11.9 million previously issued common share purchase warrants (the "IPO Warrants") and certain broker warrants.

Pursuant to the terms of the IPO Warrants, the Company's volume weighted average share price on the Canadian Securities Exchange exceeded CAD $0.35 for 20 consecutive trading days. As a result, the Company had the right to issue to holders of IPO Warrants a notice of early exercise. The Company issued a notice to holders of IPO Warrants through the Company's IPO Warrant Agent, Odyssey Trust Company, with a due date of March 16, 2021.

Over 92% of the IPO Warrants (Sept 2019) were exercised based on that notice and the remaining 8% has now expired in accordance with their terms.

"The exercise of the warrants indicates that investors are still confident in InnoCan Pharma," states, CEO, Iris Bincovich. "Following our important milestones since our IPO in September 2019, and alongside the proceeds received, we have the financial strength allowing us to accelerate our "CBD Loaded Exosomes" and "CBD-loaded liposome" proprietary programs with the Tel Aviv and the Hebrew University."

About Innocan

The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol ("CBD"). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/77503

© Newsfilecorp 2021
Copier lien
All news about INNOCAN PHARMA CORPORATION
04/06
04/01
03/23
03/16
03/10